

Fluorescent and bioluminescent reporter mouse-adapted Ebola viruses maintain pathogenicity and can be visualized *in vivo*

Katherine A. Davies, Stephen R. Welch, Shilpi Jain, Teresa Sorvillo, JoAnn Coleman-McCray, Joel M. Montgomery, Christina F. Spiropoulou, César Albariño, Jessica R. Spengler

Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA

Supplementary figures:

Figure S1. Mice inoculated SC with MA-EBOV do not demonstrate signs of infection.

Figure S2. In vivo and ex vivo visualization of MA-EBOV in CD-1 mice surviving to study endpoint.

Table S1. Clinical summary and tissue viral load in CD-1 mice infected with MA-EBOV, rMA-EBOV and reporter-protein expressing rMA-EBOV.

Table S2. Summary of bioluminescent and fluorescent imaging of CD-1 mice infected with MA-EBOV, rMA-EBOV and reporter-protein expressing rMA-EBOV.




Figure S1. Mice inoculated subcutaneously with MA-EBOV do not demonstrate clinical signs of infection.

Weight (percentage change from baseline taken at day 0), clinical signs, and survival of CD-1 mice infected subcutaneously (SC) with 1000 TCID₅₀ of MA-EBOV. Solid black lines and dashed grey lines represent the mean weight change for SC and IP infected animals, respectively. Grey dashed line on survival curve indicates survival of IP infected animals. Severity of clinical signs is indicated by the color scale (1-10).




Figure S2. *In vivo* and *ex vivo* visualization of MA-EBOV in CD-1 mice surviving to study endpoint. CD-1 mice infected intraperitoneally with 1000 TCID₅₀ of rMA-EBOV/Zn at study endpoint were injected with nLuc substrate, euthanized, and examined for bioluminescent signal *in vivo* and in organs *ex vivo* using the IVIS Spectrum CT. Relative luminescence detected is expressed as photons per second per square centimeter per steradian (p/sec/cm²/sr) indicated by the color scale. VD, ventrodorsal; DV, dorsoventral; LL, left lateral; RL, right lateral

No.	Experimental Group	DPI	Gender	Clinical Score			RT-qPCR (copies/uL RNA)														Tissue titer (TCID ₅₀ /g)							
				At euthanasia	Max	Weight Change (%)	Liver	Spleen	Testes	Seminal Vesicle	Ovary	Uterus	Kidney	Heart	Lung	Eye	Brain	Blood	Liver	Spleen	Testes	Seminal Vesicle	Ovary	Uterus	Eye	Brain		
1	Mock	14	Male	0	0	9.0%	ND	ND	ND	ND	-	-	ND	ND	ND	ND	ND	n/a	n/a	n/a	n/a	-	-	n/a	n/a			
2		14	Male	0	0	15.2%	ND	ND	ND	ND	-	-	ND	ND	ND	ND	ND	n/a	n/a	n/a	n/a	-	-	n/a	n/a			
3		14	Male	0	0	4.2%	ND	ND	ND	ND	-	-	ND	ND	ND	ND	ND	n/a	n/a	n/a	n/a	-	-	n/a	n/a			
4		14	Female	0	0	14.0%	ND	ND	-	-	ND	ND	ND	ND	ND	ND	ND	n/a	n/a	-	-	n/a	n/a	n/a	n/a			
5		14	Female	0	0	6.4%	ND	ND	-	-	ND	ND	ND	ND	ND	ND	ND	n/a	n/a	-	-	n/a	n/a	n/a	n/a			
6		14	Female	0	0	4.0%	ND	ND	-	-	ND	ND	ND	ND	ND	ND	ND	n/a	n/a	-	-	n/a	n/a	n/a	n/a			
1	MA-EBOV SC	14	Male	0	0	10.4%	ND	ND	ND	ND	-	-	ND	ND	ND	ND	ND	n/a	n/a	n/a	-	-	n/a	n/a				
2		14	Male	0	0	7.3%	ND	ND	ND	ND	-	-	ND	ND	ND	ND	ND	n/a	n/a	n/a	-	-	n/a	n/a				
3		14	Male	0	0	7.5%	ND	ND	ND	ND	-	-	ND	ND	ND	ND	ND	n/a	n/a	n/a	-	-	n/a	n/a				
4		14	Male	0	0	7.4%	ND	ND	ND	ND	-	-	ND	ND	ND	ND	ND	n/a	n/a	n/a	-	-	n/a	n/a				
5		14	Female	0	0	24.5%	ND	ND	-	-	ND	ND	ND	ND	ND	ND	ND	n/a	n/a	-	-	n/a	n/a	n/a	n/a			
6		14	Female	0	0	16.0%	ND	ND	-	-	ND	ND	ND	ND	ND	ND	ND	n/a	n/a	-	-	n/a	n/a	n/a	n/a			
7		14	Female	0	0	14.3%	ND	ND	-	-	ND	ND	ND	ND	ND	ND	ND	n/a	n/a	-	-	n/a	n/a	n/a	n/a			
8		14	Female	0	0	8.7%	ND	ND	-	-	ND	ND	ND	ND	ND	ND	ND	n/a	n/a	-	-	n/a	n/a	n/a	n/a			
1	rMA-EBOV nLuc IP	6	Male	10	10	-13.9%	2.4E+07	5.2E+05	2.3E+06	1.6E+05	-	-	1.5E+06	1.3E+06	2.7E+05	8.4E+04	ND	1.77E+05	1.5E+08	4.9E+07	6.1E+05	1.9E+05	-	-	8.6E+04	n/a		
2		6	Male	10	10	-5.1%	4.5E+07	3.7E+05	1.2E+06	9.9E+04	-	-	3.8E+05	9.9E+05	1.3E+05	4.3E+04	5.5E+02	1.31E+05	1.7E+08	5.2E+06	4.7E+06	2.2E+05	-	-	ND	3.5E+02		
3		6	Male	10	10	-13.6%	3.0E+07	6.8E+05	1.1E+06	2.1E+05	-	-	1.3E+06	1.1E+06	4.9E+05	6.1E+03	4.3E+04	2.74E+03	9.3E+07	3.4E+07	4.9E+04	5.0E+05	-	-	ND	8.3E+04		
4†		6	Female	10	10	-6.8%	4.4E+07	5.1E+06	-	-	2.1E+07	1.3E+07	3.9E+06	2.4E+06	1.2E+06	1.3E+05	4.6E+05	1.26E+06	3.7E+06	6.8E+06	-	-	3.1E+06	2.3E+07	1.0E+02	6.1E+05		
5		5	Female	10	10	-11.2%	4.3E+07	1.1E+06	-	-	2.6E+07	7.8E+06	1.0E+07	1.2E+07	3.5E+05	1.1E+05	7.6E+05	1.12E+06	6.1E+06	6.4E+06	-	-	2.9E+04	9.9E+05	2.3E+03	7.0E+05		
6		6	Female	10	10	-16.7%	3.1E+07	5.8E+05	-	-	9.3E+06	3.0E+06	6.1E+05	1.6E+06	2.2E+05	4.0E+04	1.0E+02	3.11E+04	1.3E+07	3.0E+05	-	-	7.7E+04	6.5E+03	ND	1.5E+03		
7		5	Female	10	10	-4.6%	7.6E+07	3.6E+06	-	-	3.1E+07	5.9E+06	1.7E+07	6.0E+06	2.8E+05	1.1E+05	1.3E+06	9.20E+07	2.4E+08	4.9E+07	-	-	5.2E+03	4.3E+05	6.7E+05	2.7E+07		
1	rMA-EBOV nLuc-ZsG IP	14	Male	0	6	1.1%	ND	ND	ND	ND	-	-	ND	ND	ND	ND	ND	n/a	n/a	n/a	n/a	-	-	n/a	n/a			
2		14	Male	0	6	-0.3%	ND	ND	ND	ND	-	-	ND	ND	ND	ND	ND	n/a	n/a	n/a	n/a	-	-	n/a	n/a			
3†		10	Male	10	10	-19.5%	2.7E+02	ND	ND	ND	-	-	8.1E+05	ND	6.4E+04	ND	ND	-	ND	n/a	n/a	n/a	-	-	n/a	n/a		
4†		6	Male	10	10	-11.3%	4.8E+07	5.0E+05	1.5E+05	8.5E+05	-	-	4.5E+05	1.4E+06	5.6E+05	6.1E+04	1.2E+06	-	1.6E+07	2.5E+06	2.2E+05	1.5E+06	-	-	ND	4.0E+03		
5		7	Female	10	10	-10.2%	5.4E+06	1.6E+03	-	-	1.4E+06	1.8E+06	3.0E+05	1.0E+05	ND	ND	6.90E+03	-	7.9E+04	4.0E+04	-	-	3.4E+04	5.7E+04	n/a	n/a		
6		6	Female	10	10	-12.4%	3.9E+07	6.9E+05	-	-	1.2E+07	1.5E+07	4.0E+06	2.2E+06	6.1E+04	1.6E+05	6.5E+04	3.27E+06	1.7E+08	3.0E+07	-	-	8.5E+06	1.1E+07	1.5E+03	2.5E+03		
7†		6	Female	10	10	-2.1%	5.2E+07	6.8E+05	-	-	4.2E+06	1.9E+06	1.6E+06	3.2E+06	6.8E+05	3.5E+04	6.8E+04	-	3.4E+07	8.4E+06	-	-	6.9E+05	1.9E+06	4.3E+04	3.2E+05		
8†		6	Female	10	10	-13.9%	1.2E+08	4.1E+06	-	-	1.1E+07	6.2E+06	6.9E+06	7.2E+06	2.5E+06	3.0E+05	3.0E+05	-	7.7E+07	4.5E+05	-	-	2.9E+05	4.1E+06	ND	2.6E+05		
1†	rMA-EBOV ZsG-nLuc IP	7	Male	10	10	-12.5%	1.8E+07	5.5E+04	8.6E+05	-	-	-	1.8E+04	7.2E+05	1.5E+05	7.7E+03	ND	-	3.1E+06	1.5E+05	9.7E+04	-	-	-	n/a	n/a		
2		6	Male	10	10	-9.9%	4.3E+07	1.3E+06	5.0E+06	3.8E+05	-	-	4.4E+06	3.1E+06	3.8E+04	6.3E+05	1.5E+07	7.43E+03	2.8E+07	2.8E+07	2.8E+05	2.7E+05	-	-	1.0E+02	2.3E+04		
3		14	Male	0	4	7.1%	ND	ND	ND	ND	-	-	ND	ND	8.7E+03	ND	ND	ND	n/a	n/a	n/a	n/a	-	-	n/a	n/a		
4		14	Female	0	2	6.6%	ND	ND	-	-	ND	8.7E+04	ND	ND	ND	ND	ND	ND	n/a	n/a	-	-	n/a	ND	n/a	n/a		
5		6	Female	10	10	-5.4%	1.6E+07	4.9E+05	-	-	1.4E+07	3.2E+06	4.8E+05	2.3E+06	1.6E+05	9.2E+04	1.9E+03	3.13E+04	1.3E+07	1.9E+05	-	-	2.5E+06	2.1E+06	2.5E+03	ND		
6†		6	Female	10	10	-9.4%	5.7E+07	9.6E+05	-	-	4.2E+06	2.2E+07	1.1E+06	2.1E+06	1.2E+06	9.2E+04	1.3E+06	-	1.5E+07	6.4E+06	-	-	1.3E+06	2.4E+07	ND	ND		
7†		8	Female	10	10	0.0%	3.8E+06	1.2E+04	-	-	5.4E+05	2.1E+05	ND	1.2E+05	2.5E+04	ND	ND	-	ND	ND	-	-	ND	ND	ND	ND		
1†	rMA-EBOV ZsG IP	8	Male	10	10	-9.7%	3.7E+07	2.0E+05	1.3E+05	4.3E+05	-	-	8.7E+05	2.4E+06	5.5E+05	8.9E+02	ND	-	5.7E+05	4.1E+04	3.6E+03	1.0E+03	-	-	ND	n/a		
2†		6	Male	10	10	-7.2%	1.0E+08	1.2E+06	1.9E+06	2.1E+06	-	-	1.2E+07	5.2E+06	7.3E+05	1.7E+05	4.1E+05	-	7.7E+07	4.8E+07	1.3E+06	2.8E+05	-	-	ND	1.5E+05		
3		6	Male	10	10	-8.9%	3.5E+07	2.1E+06	2.8E+06	4.2E+05	-	-	2.4E+06	5.4E+06	1.1E+06	2.5E+05	3.6E+05	8.41E+05	1.7E+08	4.3E+07	3.2E+05	1.5E+05	-	-	1.0E+05	1.1E+05		
4		6	Male	10	10	-15.9%	2.4E+07	1.7E+06	2.1E+06	9.4E+05	-	-	4.9E+06	3.1E+06	1.6E+05	3.3E+05	4.5E+05	2.32E+06	3.0E+08	2.0E+08	8.8E+06	2.2E+07	-	-	4.5E+04	4.2E+05		
5		5	Female	10	10	-8.2%	6.9E+07	3.5E+05	-	-	2.8E+07	2.5E+07	6.9E+06	5.4E+06	8.4E+04	3.6E+05	7.5E+05	1.23E+07	1.6E+08	3.9E+07	-	-	3.6E+07	8.9E+07	5.3E+04	5.2E+05		
6		5	Female	10	10	-10.0%	2.2E+08	1.2E+06	-	-	2.3E+07	2.1E+07	1.5E+07	5.1E+06	6.1E+04	4.0E+05	5.7E+05	1.34E+06	6.1E+08	7.3E+07	-	-	1.6E+07	8.5E+07	2.1E+02	2.3E+05		
7		5	Female	10	10	-14.6%	1.0E+08	1.6E+06	-	-	4.5E+06	6.7E+07	1.2E+07	5.8E+06	3.6E+05	4.0E+05	1.5E+06	4.07E+06	2.2E+08	6.7E+07	-	-	8.0E+06	1.7E+09	ND	6.0E+05		
8		5	Female	10	10	-10.1%	9.1E+07	1.8E+03	-	-	2.0E+07	3.5E+07	1.3E+07	1.5E+07	1.0E+05	1.9E+05	6.9E+05	1.05E+06	9.1E+07	1.2E+08	-	-	8.3E+07	7.6E+07	4.5E+02	1.3E+06		
1	rMA-EBOV IP	6	Male	10	10	-13.5%	4.1E+07	1.7E+06	2.9E+06	2.0E+05	-	-	1.4E+06	1.5E+06	4.2E+05	7.4E+04	2.3E+05	1.04E+05	3.0E+08	4.3E+07	9.6E+05	6.2E+05	-	-	2.1E+05	1.1E+02		
2		6	Male	10	10	-13.5%	1.2E+08	1.3E+06	2.0E+06	4.3E+05	-	-	9.2E+05	1.8E+06	8.9E+04	8.7E+04	1.8E+04	2.36E+05	1.9E+08	3.6E+07	3.6E+05	8.8E+05	-	-	9.0E+02	4.6E+03		
3		5	Male	10	10	-12.6%	1.8E+07	1.1E+06	4.4E+06	8.1E+05	-	-	1.2E+07	1.0E+07	5.0E+04	2.6E+05	1.3E+06	1.68E+04	3.5E+08	1.4E+08	4.6E+06	4.9E+05	-	-	1.9E+04	2.8E+05		
4		6	Male	10	10	-20.6%	8.0E+08	3.2E+05	1.5E+05	1.2E+06	-	-	2.0E+07	4.9E+05	3.8E+05	1.2E+04	4.7E+07	ND	1.6E+08	3.3E+07	3.0E+06	2.5E+07	-	-	4.2E+04	2.2E+05		
5		5	Female	10	10	-6.0%	2.3E+07	1.5E+06	-	-	7.1E+06	3.0E+06	2.0E+06	1.3E+07	5.6E+06	3.8E+04	9.8E+05	3.63E+06	1.4E+08	7.7E+07	-	-	1.5E+07	4.1E+07	1.7E+05	1.4E+06		
6		5	Female	10	10	-11.1%	2.3E+07	4.2E+06	-	-	1.3E+07	4.3E+07	7.8E+06	3.5E+06	2.0E+06	8.2E+04	6.6E+05	7.21E+05	4.5E+08	6.6E+07	-	-	1.7E+07	2.0E+08	2.5			

No.	Experimental Group	DPI	Gender	Clinical Score			Bioluminescence Detection								Fluorescence Detection (Epi-Illumination)								Fluorescence Detection (Blue-Light Transillumination)									
				At euthanasia	Max	Weight Change (%)	Liver	Spleen	Testes	Seminal Vesicle	Ovary	Uterus	Eye	Brain	Liver	Spleen	Testes	Seminal Vesicle	Ovary	Uterus	Eye	Brain	Liver	Spleen	Testes	Seminal Vesicle	Ovary	Uterus	Eye	Brain		
1	Mock	14	Male	0	0	9.0%	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	ND	ND	ND	ND	-	-	ND	ND		
2		14	Male	0	0	15.2%	ND	ND	ND	ND	-	-	ND	ND	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	
3		14	Male	0	0	4.2%	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	
4		14	Female	0	0	14.0%	ND	ND	-	-	ND	ND	ND	ND	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	
5		14	Female	0	0	6.4%	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	
6		14	Female	0	0	4.0%	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	
1	MA-EBOV SC	14	Male	0	0	10.4%	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	
2		14	Male	0	0	7.3%	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	
3		14	Male	0	0	7.5%	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	
4		14	Male	0	0	7.4%	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	
5		14	Female	0	0	24.5%	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	
6		14	Female	0	0	16.0%	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	
7		14	Female	0	0	14.3%	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	
8		14	Female	0	0	8.7%	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	
1	rMA-EBOV nLuc IP	6	Male	10	10	-13.9%	D	D	D	D	-	-	ND	ND	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	
2		6	Male	10	10	-5.1%	D	D	D	D	-	-	ND	ND	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	
3		6	Male	10	10	-13.6%	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	
4†		6	Female	10	10	-6.8%	n/a	n/a	n/a	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	
5		5	Female	10	10	-11.2%	D	D	-	-	D	D	ND	ND	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	
6		6	Female	10	10	-16.7%	D	D	-	-	D	D	ND	ND	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	
7		5	Female	10	10	-4.6%	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	
1	rMA-EBOV nLuc-ZsG IP	14	Male	0	6	1.1%	D	D	D	D	-	-	ND	ND	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	
2		14	Male	0	6	-0.3%	n/a	n/a	n/a	n/a	-	-	n/a	n/a	ND	ND	D	ND	-	-	ND	ND	ND	ND	D	ND	-	-	ND	ND		
3†		10	Male	10	10	-19.5%	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a		
4†		6	Male	10	10	-11.3%	n/a	n/a	n/a	n/a	-	-	n/a	n/a	D	D	D	D	-	-	D	D	n/a	n/a	n/a	n/a	-	-	n/a	n/a		
5		7	Female	10	10	-10.2%	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a		
6		6	Female	10	10	-12.4%	D	D	-	-	D	D	ND	ND	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	D	D	-	-	D	D
7†		6	Female	10	10	-2.1%	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	
8†		6	Female	10	10	-13.9%	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	D	D	D	D	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	
1†	rMA-EBOV ZsG-nLuc IP	7	Male	10	10	-12.5%	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	
2		6	Male	10	10	-9.9%	D	D	D	D	-	-	ND	ND	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	D	D	-	-	ND	ND
3		14	Male	0	4	7.1%	D	ND	ND	D	-	-	ND	ND	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	ND	ND	ND	ND	-	-	ND	ND
4		14	Female	0	2	6.6%	ND	ND	-	-	ND	D	ND	ND	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	ND	ND	-	-	ND	D	ND	ND
5		6	Female	10	10	-5.4%	D	D	-	-	D	D	ND	ND	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	
6†		6	Female	10	10	-9.4%	n/a	n/a	-	-	n/a	n/a	n/a	n/a	D	ND	-	-	D	D	ND	ND	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	
7†		8	Female	10	10	0.0%	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	
1†		8	Male	10	10	-9.7%	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	
2†	rMA-EBOV ZsG IP	6	Male	10	10	-7.2%	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	
3		6	Male	10	10	-8.9%	n/a	n/a	n/a	n/a	-	-	n/a	n/a	D	D	D	D	-	-	D	ND	n/a	n/a	D	D	D	-	-	D	D	
4		6	Male	10	10	-15.9%	n/a	n/a	n/a	n/a	-	-	n/a	n/a	D	D	D	D	-	-	D	D	n/a	n/a	D	D	D	-	-	D	D	
5		5	Female	10	10	-8.2%	n/a	n/a	-	-	n/a	n/a	n/a	n/a	D	D	-	-	D	D	ND	ND	n/a	n/a	D	D	-	-	D	D	D	
6		5	Female	10	10	-10.0%	n/a	n/a	-	-	n/a	n/a	n/a	n/a	D	D	-	-	D	D	ND	ND	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	
7		5	Female	10	10	-14.6%	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	
8		5	Female	10	10	-10.1%	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	
1		rMA-EBOV IP	6	Male	10	10	-13.5%	ND	ND	ND	ND	-	-	ND	ND	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a
2	6		Male	10	10	-13.5%	ND	ND	ND	ND	-	-	ND	ND	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	
3	5		Male	10	10	-12.6%	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	
4	6		Male	10	10	-20.6%	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	
5	5		Female	10	10	-6.0%	ND	ND	-	-	ND	ND	ND	ND	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	
6	5		Female	10	10	-11.1%	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	
7	5		Female	10	10	-17.8%	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	
8	5		Female	10	10	-19.7%	n/a	n/a	-	-	n/a	n/a	n/a	n/a	ND	ND	-	-	ND	ND	ND	ND	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	
1	MA-EBOV IP	6	Male	10	10	-12.3%	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	
2		5	Male	10	10	-10.8%	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	
3		6	Male	10	10	-13.1%	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	
4		6	Male	10	10	-6.1%	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	